Comparing anti-tau antibodies under clinical trials and their epitopes on tau pathologies

Mol Neurodegener. 2024 Oct 19;19(1):76. doi: 10.1186/s13024-024-00769-x.

Ha-Lim Song^#¹, Min-Seok Kim^#¹, Woo-Young Cho², Ye-Seul Yoo², Jae-You Kim², Tae-Wook Kim², Hyori Kim³, Dong-Hou Kim², Seung-Yong Yoon^{4

5

6}

¹ ADEL Institute of Science & Technology (AIST), ADEL, Inc, Seoul, Korea.
² Department of Brain Science, Asan Medical Center, University of Ulsan College of Medicine, Brain Korea 21 project, Seoul, Korea.
³ Convergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, South Korea.
⁴ ADEL Institute of Science & Technology (AIST), ADEL, Inc, Seoul, Korea. [email protected].
⁵ Department of Brain Science, Asan Medical Center, University of Ulsan College of Medicine, Brain Korea 21 project, Seoul, Korea. [email protected].
⁶ Stem Cell Immunomodulation Research Center (SCIRC), University of Ulsan College of Medicine, Seoul, Korea. [email protected].

^# Contributed equally.

No abstract available

Publication types